SLIDE 4 10/6/2017 4
Cost/benefit of therapeutic radiation
- Called “radiation oncology” or “radiation therapy”
- Therapeutic radiation after surgery is usually justified
based on a 20-25% reduction in cancer recurrence
- Therapeutic radiation (without preceding surgery) is
usually justified for at least 50% chance of cure
- This is balanced against the known risks of acute
toxicity (usually severe for some weeks) as well as the <1% increased risk of “radiation induced malignancy” over the general risk
Radiation induced malignancy
- Radiation-induced leukemias (blood cancers)
typically require 2–10 years to appear – much higher risk from chemotherapy rather than radiation
- Radiation-induced solid tumors usually take 10–15
years to clinically manifest
- French breast cancer radiation patients:
increased risk of sarcoma of 0.28% to 0.48%
- United States and Sweden breast cancer
radiation patients: 0.5% increased lung cancer risk but only seen in smokers
Risk is very dependent on individual characteristics
- Whole body radiation is highest risk; then site specific e.g. highest
risk to testes, cervix, non-limb soft tissue, salivary gland, with low risk to orbit, oral/pharynx/larynx, female breast
- Recent SEER database study: of 647,672 patients, 60,271 (8%) had
a second cancer but only 3,266 (0.5%) were related to radiation
- 5 excess cancers per 1000 radiotherapy patients at 15 years after
diagnosis
- Much greater risks of cancer from lifestyle (e.g. smoking),
carcinogenic exposures, and genetics
- Persons with complex genetic syndromes e.g. retinoblastoma, are
more susceptible
- Children and adolescents are twice as likely to develop radiation-
induced leukemia as adults, and live longer to develop solid cancers
de Gonzalez et al, Lancet Oncology April 2011
Radiation safety is based
- n the ALARA principle
- ALARA = “As Low As Reasonably Achievable”
- Radiation protection guidelines are based on the
“linear no-threshold” model of risk
- Assumes that no dose of radiation is safe – this
model is very conservative and overestimates risk
- One millisievert (100 mrem) 0.0055% chance of
eventually developing cancer
- 6.2 mSv (average annual exposure) 0.0341%
baseline risk